Elevated Sera sST2 Is Associated With Heart Failure in Men 50 Years Old With Myocarditis

Michael J Coronado1, Katelyn A Bruno1,2, Lori A Blauwet3

  • 11 Department of Environmental Health Sciences Johns Hopkins Bloomberg School of Public Health Baltimore MD.

Insights

Soluble ST2 (sST2) levels are higher in men with myocarditis and predict heart failure risk in younger men. Testosterone may increase sST2 levels, contributing to sex differences in myocarditis outcomes.

Area of Science:

  • Cardiology
  • Immunology
  • Endocrinology

Background:

  • Myocarditis is a significant cause of heart failure with poorer outcomes in men.
  • The underlying reasons for sex-based disparities in myocarditis recovery are not fully understood.
  • Soluble ST2 (sST2), a marker of cardiac stress, has not been previously investigated in myocarditis.

Purpose of the Study:

  • To investigate sex differences in soluble ST2 (sST2) levels in patients with myocarditis.
  • To determine the association of sST2 with heart failure severity and cardiac inflammation in myocarditis.
  • To explore the role of sex hormones in regulating sST2 levels in myocarditis.

Main Methods:

  • Adults with clinically suspected myocarditis (n=303, 78% male) were analyzed.
  • Serum sST2 levels were measured using ELISA in human patients and male mice.
  • Correlations between sST2, cardiac function (NYHA class), sex, age, and cardiac inflammation were assessed.

Main Results:

  • Men with myocarditis exhibited higher sST2 levels than women.
  • Elevated sST2 was associated with New York Heart Association (NYHA) class III-IV heart failure, particularly in men.
  • In male mice, myocarditis increased sST2 levels, linked to cardiac inflammation; testosterone administration elevated sST2.

Conclusions:

  • Elevated serum sST2 is linked to increased heart failure risk in younger men (≤50 years) with myocarditis.
  • Testosterone appears to influence sST2 levels, potentially explaining sex differences in myocarditis severity.
  • sST2 may serve as a biomarker for heart failure risk stratification in male myocarditis patients.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
907
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.6K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
877
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
332
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
963
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
308